AstraZeneca to divest part of antibiotics business in up to $1.5 billion deal

24 August 2016
astrazeneca-large

Anglo-Swedish pharma major AstraZeneca (LSE: AZN) has entered into an agreement with US giant Pfizer (NYSE: PFE) to sell the commercialization and development rights to its late-stage small molecule antibiotics business in most markets globally outside the USA.

The deal follows Monday’s news that Pfizer has also agreed a $14 billion transaction to acquire US biotech firm Medivation to expand its oncology business, and follows several asset sales by AstraZeneca, whose shares were barely moved by the latest news.

The agreement reinforces AstraZeneca’s focus on developing transformational medicines in its three main therapy areas, while realizing value from the strong portfolio of established and late-stage small molecule antibiotics through Pfizer’s dedicated commercialisation and development capabilities in anti-infectives. The portfolio comprises the approved antibiotics Merrem(meropenem) and Zinforo (ceftaroline fosamil), which are available in more than 100 countries and generated sales of $250 million in 2015, and Zavicefta(ceftazidime-avibactam), as well as ATM-AVI and CXL, which are in clinical development.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical